Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endpoints for lymphatic filariasis programs.

Caroline A Grady1, Madsen Beau de Rochars, Abdel N Direny

  • 1Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.

Emerging Infectious Diseases
|June 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A framework for guiding integrated disease control measures through multipathogen surveillance.

medRxiv : the preprint server for health sciences·2025
Same author

Characterizing trachoma elimination using serology.

Nature communications·2025
Same author

Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis.

The Lancet. Infectious diseases·2024
Same author

Characterizing trachoma elimination using serology.

medRxiv : the preprint server for health sciences·2024
Same author

Over 25 Years of Hope: Development of Lymphatic Filariasis Patient Support Groups in Haiti.

The American journal of tropical medicine and hygiene·2024
Same author

Optimized strategy for real-time qPCR detection of Onchocerca volvulus DNA in pooled Simulium sp. blackfly vectors.

PLoS neglected tropical diseases·2023
Same journal

Detection of and Early Genomic Insights into Chikungunya Virus, Bolivia, 2025.

Emerging infectious diseases·2026
Same journal

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same journal

New World Ocular Dirofilariasis Caused by Dirofilaria repens Infection, United States.

Emerging infectious diseases·2026
Same journal

Angiostrongylus cantonensis Rat Lungworm Detected in Rats, Madagascar, 2022-2023.

Emerging infectious diseases·2026
Same journal

Human Pulmonary Dirofilariasis,
North Queensland, Australia, 2023<sup>1</sup>.

Emerging infectious diseases·2026
Same journal

Trends in Congenital Syphilis Cases by Maternal Country of Birth, Spain, 2016-2024.

Emerging infectious diseases·2026
See all related articles

Annual mass drug administration in Haiti reduced key indicators of lymphatic filariasis (LF). However, lymphatic filariasis transmission persisted despite five years of diethylcarbamazine and albendazole treatment.

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Public Health

Background:

  • Lymphatic filariasis (LF) is a debilitating neglected tropical disease.
  • Mass drug administration (MDA) with diethylcarbamazine and albendazole is a key strategy for LF elimination.
  • Interrupting LF transmission requires sustained and effective interventions.

Purpose of the Study:

  • To evaluate the impact of MDA on LF transmission in Leogane Commune, Haiti.
  • To assess the effectiveness of diethylcarbamazine and albendazole in interrupting LF transmission.
  • To understand the implications of findings for global LF elimination programs.

Main Methods:

  • Annual mass administration of diethylcarbamazine and albendazole over five years.
  • Monitoring of microfilaremia and antigenemia in the human population.

Related Experiment Videos

  • Assessment of mosquito infection rates to determine transmission dynamics.

    • Main Results:

    • Significant reductions in microfilaremia, antigenemia, and mosquito infection rates were observed.
    • Despite reductions, LF transmission was not interrupted after five years of MDA.
    • Persistence of LF transmission highlights challenges in elimination programs.

    Conclusions:

    • Sustained MDA with diethylcarbamazine and albendazole can reduce LF disease burden but may not be sufficient to interrupt transmission alone.
    • Alternative or supplementary strategies may be necessary for achieving LF elimination in certain settings.
    • These findings have critical implications for the design and implementation of LF elimination programs worldwide.